AstraZeneca Pharma gets permission from DCGI for Acalabrutinib Capsules
13th Mar 2020

AstraZeneca Pharma India has received Import and Market permission in Form CT-20 (Marketing Authorization - Additional Indication) from the Drugs Controller General of India (DCGI) for Acalabrutinib 100 mg capsules (Calquence).

The receipt of this Import and Market permission paves way for the launch of Acalabrutinib 100 mg capsules (Calquence) in India, subject to the receipt of related statutory approvals and licenses. Acalabrutinib 100 mg capsules is indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.